PremiumThe FlyJohnson & Johnson’s rybrevant plus lazcluze featured in lung cancer presentation Investors’ Fed Meeting Worries Weigh Down the Dow Jones Today Trump Trade: Administration explores simplified plans for reciprocal tariffs PremiumRatingsJohnson & Johnson’s Strategic Shift to Comprehensive Procedural Solutions Drives Buy Rating Rallybio reports Q4 EPS (25c), consensus (30c) Johnson & Johnson’s Icotrokinra: Strong Phase 3 Results and Market Potential Reinforce Buy Rating PremiumThe FlyExpectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley JPMorgan expects ‘significant’ underperformance of Genmab shares Johnson & Johnson call volume above normal and directionally bullish 
